ASCO GU 2024

BRCAAway - practice changing or hypothesis generating data?

Cabo + IO: Interesting but not practice changing?!

Is "more" always better?

Combination vs. monotherapy - a great new option for high-risk patients

Evaluating the recombination-repair mutations in patients with mCRPC

Cognitive function in ART treatment

Higher radiation is effective in high-risk PCA

Localized PCa - news for radiotherapy and biochemical recurrence

Enzalutamide therapy as option for biochemical recurrence

Relugolix combined with androgen signaling in real word experience

Still a difficult time for androgenic inhibitors in mCRPC

Combination of cabozantinib & checkpoint inhibitor

BRCAaway - PARP combination study

Quality of life under intensive therapy

Stockholm3 validated in multiethnic cohort

Therapy Intensification Still Neglected in mHSPC

Dose de-escalation in different ways

Further testing before olaparib combination

First positive study of IO therapy in mCRPC

Combination NHT + PARP makes sense

Gleason 3+3 - cancer or not?

What about the clinical benefit?

Insights and news for mCRPC

Olaparib + Arbiraterone better compared to either alone

Salvage radiation with anti-androgen superior to radiation alone

Long-term dose escalation - Therapy in high-risk prostate cancers

Gleason 3+3 ska vi kalla de cancer eller inte?

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

BRCAAway - PARP hämmare, abiraterone eller i kombination

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Kognitiv påverkan av abirateron och enzalutamid?

Kombination av cabozantinib och immunterapi

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Advances in (neo)-adjuvant treatment in urothelial cancer

Pembrolizumab adjuvant in bladder cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

EV + Pembro new first-line standard in localized metastatic bladder cancer

ASCO GU24 - Highlights in Bladder cancer

MIBC: adjuvant PD1 - all set?!

Update on EV-302

HER2 and bladder cancer

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Perioperative adjuvant therapy in urothelial cancer

EV as standard in 3rd line mUC

Another success for an ICI?

Biomarker update

Update M1 urothelial cancer

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Highlights in bladder cancer at ASCO GU24

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Terapia adyuvante perioperatoria en el cáncer de vejiga

Subcutaneous vs. intravenous application: ready for everyday clinics?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

No surprise with the QoL data

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Highlights in kidney cancer at ASCO GU24

Perioperative treatment in renal cell carcinoma - did we close the circle?

Better QoL with Belzutifan

ASCO GU24 - Highlights in renal cell carcinoma

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Belzutifan: Updates on QoL

Practice changing adjuvant therapy?!

Overall survival benefit - Pembro after surgery

Long-term outcome

Tumorburden and outcome

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Durable effects of Ipi-Nivo

Long-Term Data on NIVO+IPI in aRCC

Long-term follow-up of first-line trials

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24